Unidentified
Ontology highlight
ABSTRACT:
PROVIDER: PRJDB20067 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Microarray analysis of gene expression profiles in response to tomato leaves extract treatment in MCF-7 breast cancer cells
2025-01-24 | E-GEOD-33443 | ExpressionAtlas
Project description:Gene expression profiles of breast cancer subtypes are detectable in histologically normal breast epithelium
2025-01-24 | E-GEOD-21947 | ExpressionAtlas
Project description:Transcription profiling by array of MCF7 breast cancer cells after treatment with doxorubicin
2025-01-24 | E-GEOD-39870 | ExpressionAtlas
Project description:Characterization of gene expression profiles induced by HIC-1 reactivation on breast cancer
2025-01-24 | E-GEOD-42024 | ExpressionAtlas
Project description:In patients with primary breast cancer, neoadjuvant chemotherapy with doxorubicin plus pemetrexed followed by docetaxel (AP-D) is associated with a pathologic complete response (pCR) rate of 16.5%, and doxorubicin plus cyclophosphamide followed by docetaxel (AC-D) is associated with a pCR rate of 20.2%. Our primary objective was to identify single predictive genetic markers for achievement of pCR following either AP-D or AC-D treatment. Our main secondary objective was to detect treatment-group specific, pCR-predictive gene signatures.
2014-02-01 | E-TABM-1186 | biostudies-arrayexpress
Project description:Gene expression profiling in patients with polymyalgia rheumatica before and after symptom abolishing glucocorticoid treatment
2025-01-23 | E-MTAB-3671 | ExpressionAtlas
Project description:Breast cancer is the most frequently diagnosed female cancer accounting for 23 % of the total cases and the second leading cause of cancer mortality in the world, particularly in western countries. Since GEPARDUO trial reported the therapeutic benefit of combined doxorubicin and cyclophosphamide regimen in sequential administration with docetaxel, the combination regimen has become a standard therapeutic strategy in neoadjuvant systemic therapy for patients with operable breast cancers regardless of an intrinsic subtype. Although approximately 70% of entire patients are currently receiving the chemotherapy regimen, pathologic complete response (pCR) rate is still low, ranging from 23% to 32.7% due to the high heterogeneity of breast cancers. Therefore, the need for a marker predictive of response to a particular cytotoxic regimen, especially before neoadjuvant chemotherapy, is becoming all the more necessary to optimize therapeutic efficacy and to avoid unnecessary complications caused by systemic therapy. In the study, here we generated the first high-coverage proteomic data for needle biopsy FFPE sample being characterized with identical clinical conditions including chemotherapeutic regimens and the stage classification.
2021-09-08 | PXD013431 | Pride
Project description:Gene expression profiles of pretreatment biopsies from dose-dense-docetaxel-treated breast cancers
| PRJNA138815 | ENA
Project description:Gene expression profiles in CLL
2025-01-24 | E-GEOD-22529 | ExpressionAtlas
Project description:Investigation of gene expression in biopsies from psoriasis patients before and after adalimumab treatment. Paired biopsies from non-lesional and lesional before treatment start and from psoriatic skin four and 14 days treatment start were included.
2025-01-23 | E-MTAB-5262 | ExpressionAtlas